Keros Therapeutics (NASDAQ:KROS) Director Nima Farzan Sells 2,625 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS traded down $0.30 during trading on Monday, reaching $10.00. 169,361 shares of the company were exchanged, compared to its average volume of 378,172. The firm has a market capitalization of $197.92 million, a PE ratio of -3.32 and a beta of 0.94. The business’s fifty day simple moving average is $11.33 and its 200-day simple moving average is $15.15. Keros Therapeutics, Inc. has a 12-month low of $9.79 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC raised its position in Keros Therapeutics by 416.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock worth $1,074,000 after buying an additional 78,467 shares during the last quarter. Empowered Funds LLC raised its position in Keros Therapeutics by 142.2% during the 1st quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock worth $1,607,000 after buying an additional 85,439 shares during the last quarter. Quantinno Capital Management LP raised its position in Keros Therapeutics by 12.5% during the 1st quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock worth $262,000 after buying an additional 2,639 shares during the last quarter. Lazard Asset Management LLC purchased a new position in Keros Therapeutics during the 1st quarter worth approximately $129,000. Finally, Globeflex Capital L P purchased a new position in Keros Therapeutics during the 1st quarter worth approximately $418,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KROS has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.